Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD

The purpose of this study is to build upon the success the novel approach and software for
analyzing electroencephalography (EEG) data to identify biomarkers of ADHD in adults by
further refining the method. Then to test the ability of this new assessment tool to
differentiate between adults with ADHD and healthy controls by comparing the classification
accuracy of the metrics from the new tool to the classification accuracy of existing
behavioral tests for ADHD.

Inclusion Criteria:

Specific inclusion criteria for ADHD are:

1. meet established Diagnositic and Statistical Manual-5 criteria for ADHD predominately
inattentive or combined subtype with clinically significant levels of impairment,
diagnosed by structured clinical interview, the Mini International Neuropsychiatric
Interview, and corroborating information

2. Clinical Global Impression—Severity (CGI-S) score ≥ 4 for ADHD

3. no lifetime history of DSM-5 bipolar disorder, psychotic disorder, pervasive
developmental disorder, obsessive-compulsive disorder, substance abuse, or substance
dependence (except nicotine) as assessed with the Mini International Neuropsychiatric
Interview (MINI).

4. able in the opinion of the investigator to complete all required study procedures.

Exclusion Criteria:

Exclusion criteria for both groups are:

1. History of diagnosis of childhood disorder other than ADHD (e.g. autism, dyslexia)

2. history of any general medical condition likely to require chronic use of medication
with identified central nervous system (CNS) effects suspected to alter cognitive
performance

3. history of seizure disorder, brain tumor, other major neurological disorder or head
injury resulting in loss of consciousness

4. serious oxygen deprivation

5. current psychopathology requiring ongoing treatment with antipsychotic medications,
mood stabilizers, benzodiazepines, or anticonvulsants

6. current untreated psychopathology which is rated to be primary in terms of severity
(greater than ADHD severity)

7. current treatment with guanfacine.